NCT03373760 2023-06-09
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
Clinical Trials
5 trialsNCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT02766335 2023-05-25
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 2/3 Completed
NCT03574753 2021-10-18
Lung-MAP S1400K: c-MET Positive
SWOG Cancer Research Network
Phase 2 Completed
NCT02785913 2020-10-23
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network
Phase 2 Completed